Bayer buys BlueRock in USD 600 million bet on stem cell therapies Medical Dialogues Bureau9 Aug 2019 9:00 AM ISTFRANKFURT: German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up...